Poster Session A
Saturday, Sept. 14, 2019
5-7:30 p.m.

A01 Specific targeting of adipose tissue-associated metastasis using bile salt nanoparticles. Ayesha Alvero, Yale University, New Haven, CT, USA.

A02 CBX7 binds TWIST-1’s E-box to inhibit TWIST-1 function and curtail tumorigenecity and metastatic potential in ovarian cancer. Ayesha Alvero, Yale University, New Haven, CT, USA.

A03 PrOTYPE (Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE): The development and validation of a clinical-grade consensus classifier for the molecular subtypes of high grade serous tubo-ovarian cancer. Michael Anglesio, University of British Columbia, Vancouver, BC, Canada.

A04 Real-world usage of NGS testing in high-grade serous ovarian cancer (HGSOC): The landscape is quickly changing. Rebecca Arend, University of Alabama at Birmingham, Birmingham, AL, USA.

A05 Maintenance therapy for platinum-sensitive (PS) recurrent ovarian cancer (rOC): What are we actually choosing? Hannah Beer, University of Alabama at Birmingham, Birmingham, AL, USA.

A06 Synthetic peptides derived from the cell adhesion molecule Nectin-4 inhibit the formation of ovarian cancer 3D spheroids. Kristin Boylan, University of Minnesota, Minneapolis, MN, USA.

A07 A phase II study of metformin therapy in ovarian cancer with translational endpoints. Ronald Buckanovich, University of Pittsburgh, Pittsburgh, PA, USA.

A08 A new driver pathway in ovarian cancer stem cells. Ugo Cavallaro, European Institute of Oncology, Milano, Italy.

A09 SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong inhibition of the Wnt signaling pathway and antitumor effects in diverse ovarian cancer models. Heekyung Chung, Samumed, LLC, San Diego, CA, USA.

A10 Phenotypic and genomic characterization of intra-tumoral heterogeneity in high-grade serous ovarian cancer. Paula Cunnea, Imperial College, London, UK.

A11 Copy-number analysis of understudied black women ovarian cancers. Joe Delaney, Medical University of South Carolina, Charleston, SC, USA.

A12 Analysis of advanced quantitative computed tomography imaging features in predicting the surgical resectability of advanced epithelial ovarian cancer. Paul DiSilvestro, Women And Infants Hospital, Providence, RI, USA.
A13 Therapeutic AXL inhibition with AVB-S6-500 improves response to chemotherapy and induces a homologous recombination deficiency in ovarian cancer. Katherine Fuh, Washington University School of Medicine, St. Louis, MO, USA.

A14 The chemopreventive effects of natural compounds in Romina strawberries in human ovarian cancer cells. Raisa Haq, City College of New York, CUNY School of Medicine, New York, NY, USA.

A15 Non-canonical NF-kappaB signaling is associated with poor ovarian cancer prognosis. Demetra Hufnagel, Vanderbilt University School of Medicine, Nashville, TN, USA.

A16 A novel death receptor ligand fabclavine inhibits cancer and cancer stem cell proliferation by extrinsic apoptosis. Arvinder Kapur, University of Wisconsin, Madison, WI, USA.

A17 Characterization of primary-metastasis pairs in high-grade serous ovarian cancer with short- and long-term survival. Emilee Kotnik, Washington University in St. Louis, Saint Louis, MO, USA.

A18 Evaluating the potential to repurpose statins for ovarian cancer therapy. Paul Kroeger, University of Pennsylvania, Philadelphia, PA, USA.

A19, PR03 Single cell proteomic analysis of the tumoral heterogeneity in response to PARP inhibitor. Marilyne Labrie, OHSU, Portland, OR, USA.

A20 Characterizing chromosome instability in chemonaive, chemosensitive, and chemoresistant high-grade serous ovarian cancer. Claire Morden, University of Manitoba, and Research Institute in Oncology and Hemotology, Winnipeg, MB, Canada.

A21 Digital vivarium cloud platform facilitates nonclinical endpoint assessment in an ovarian carcinoma xenograft model with ascites. Chibueze Nwagwu, OncoSynergy, Inc., Greenwich, CT, USA.

A22 Synchronous ovarian and uterine cancers in US women, 2004-2015. Mary Puckett, Centers for Disease Control and Prevention, Division of Cancer Prevention and Control, Atlanta, GA, USA.

A23 Ultra-rapid total abdominal FLASH irradiation in a preclinical model of ovarian cancer. Erinn Rankin, Stanford University, Stanford, CA, USA.

A24 Cell adhesion molecule (CAM)-related downregulated by oncogenes (CDON) promotes ovarian cancer adhesion and survival. Valerie Sodi, Fox Chase Cancer Center, Philadelphia, PA, USA.
A25 Withaferin A ameliorates ovarian cancer-induced cachexia through regulation of NF-kB/NLRP3 signaling. Alex Straughn, James Graham Brown Cancer Center, Louisville, KY, USA.

A26 Molecular analysis of short- vs. long-term ovarian cancer survivors. Elaine Stur, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

A27 Microsatellite instability and tumor mutation burden as factors in ovarian clear cell carcinoma therapy selection. Shiro Takamatsu, Kyoto University Graduate School of Medicine, Kyoto, Japan.

A28 Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtypes and change in treatment course. Hisamitsu Takaya, Kindai University, Osaka-sayama, Japan.

A29 Anti-cancer effects of polo-like kinase-4 inhibitor (CFI-400945) in ovarian cancer. Ka Yu Tse, The University of Hong Kong, Hong Kong, Hong Kong.

A30 Claudin-4-dependent mechanisms of high-grade serous ovarian cancer progression. Patricia Webb, The University of Colorado, Aurora, CO, USA.

A31 The two most potent PARP inhibitors increase expression levels of innate immune response genes in BRCA wild-type HGSC tumors. Monica Wielgos-Bonvallet, NYU Langone Medical Center, New York, NY, USA.

A32 Combination panobinostat and olaparib treatment promotes DNA damage and anti-tumor immunity in ovarian cancer. Andrew Wilson, Vanderbilt University Medical Center, Nashville, TN, USA.

A33 Loss of ZC3H18 disrupts homologous recombination repair and sensitizes ovarian cancer cells to PARP inhibitors and DNA cross-linking agents. Arun Kanakkanthara, Mayo Clinic, Rochester, MN, USA.

A34 Targeting protein phosphatase 2A in combination with PARP inhibitors for the treatment of high-grade serous epithelial ovarian cancer. Rita A. Avelar, University of Michigan, Ann Arbor, MI, USA.

A35 Targeting the IDH1-mediated metabolic-epigenetic axis in cyclin E-high ovarian cancer. Katherine Aird, Penn State College of Medicine, Hershey, PA, USA.

A36 Developing a novel treatment for advanced ovarian cancer by targeting the c-Met pathway. Anusha Chaparala, Northwestern University, Chicago, IL, USA.
A37 PAX8 drives ovarian cancer angiogenesis through interaction with SOX17. Daniele Chaves-Moreira, University of Pennsylvania, Philadelphia, PA, USA.

A38 ATM inhibitor synergizes with glycolysis inhibition in ovarian cancer cells. Chi-Wei Chen, Penn State College of Medicine, Hershey, PA, USA.

A39 Understanding poly-ADP-ribose polymerase (PARP) inhibitor resistance in BRCA2-deficient cells through dual CRISPR knockout and activation screens. Kristen Clements, Pennsylvania State University College of Medicine, Hershey, PA, USA.

A40 Singling out tumor heterogeneity and chemoresistance in high-grade serous ovarian cancer. Erdogan Pekcan Erkan, University of Helsinki, Helsinki, Finland.

A41 ROR1 is associated with ovarian cancer progression and chemoresistance. Caroline Ford, UNSW Sydney, Sydney, NSW, Australia.

A42 Potassium channel activity unveils ovarian cancer vulnerability: From signaling to precision medicine. Saverio Gentile, University of Illinois Chicago, Chicago, IL, USA.

A43 Centrosome amplification favours survival and impairs ovarian cancer progression. Oumou Goundiam, Institut Curie, Paris, France.

A44 A CRISPRi screen to identify combination therapies for improved treatment of ovarian cancer. Erika Handly, MIT, Cambridge, MA, USA.

A45 Quinacrine induces necrosis of ovarian high-grade serous carcinoma cells by breaking the mitochondria ROS balance. Ching-I Huang, Tzu Chi University, Hualien, Republic of China.

A46, PR01 Assessment of PARPi and cisplatin resistance in BRCA1 exon 11 mutant patient-derived xenografts. John Krais, Fox Chase Cancer Center, Philadelphia, PA, USA.

A47 Preclinical efficacy of CPI-1688, a novel EZH2 inhibitor, in epithelial ovarian cancer with alterations in the SWI/SNF chromatin remodeling complex. Elizabeth Magno, The Wistar Institute, Philadelphia, PA, USA.

A48 Anti-apoptotic gene expression and sensitivity to BH3-mimetics in chemo-resistant, high-grade serous ovarian cancer cell lines. Cristina Mapagu, Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, NSW, Australia.
A49 Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma. Noriomi Matsumura, Kindai University, Osakasayama, Osaka, Japan.

A50 Lapatinib potentiates the anti-tumor effects of paclitaxel treatment in resistant ovarian cancer cells. Rob McCorkle, University of Kentucky, Lexington, KY, USA.

A51 The role of ATF6-mediate AP-1 signaling in promoting PARP inhibitor resistant ovarian cancer. Alexandra McMellen, University of Colorado Denver, Aurora, CO, USA.

A52 Serially passing ovarian cancer spheroids as an in situ model for emergence of chemoresistance and enrichment of cancer stem cells. Geeta Mehta, University of Michigan, Ann Arbor, MI, USA.

A53 Energetic regulation of the Cyclin E onco-protein in mitochondria-dependent ovarian tumor initiating cells. Kasturi Mitra, University of Alabama, Birmingham, AL, USA.

A54 Targeting new links in the proteostasis network as novel therapies in high-grade serous ovarian cancer. Sumegha Mitra, Indiana University School of Medicine, Indianapolis, IN, USA.

A55 DCLK1 mediates tumor stemness and platinum resistance in high-grade serous epithelial ovarian cancer. Katherine Moxley, University of Oklahoma Stephenson Cancer Center, Oklahoma City, OK, USA.

A56 Novel L-sugar linked glycosylated antitumor ether lipids for killing platinum-resistant human epithelial ovarian cancer cells. Mark Nachtigal, University of Manitoba, Winnipeg, MB, Canada.

A57 Identification of novel targets for ovarian cancer treatment. Ricardo Noriega, University of Puerto Rico Medical Sciences Campus, San Juan, PR, USA.

A58 HR-ESI-MS identification of novel triterpenoid antitumor substances in securidaca 1, using activity-guided SRB assay. Titus Obasi, Iuliu Hatieganu University of Medicine and Pharmacy (UMF), Cluj-Napoca, Cluj, Romania.

A59 RNA-seq analysis of high-grade serous ovarian cancer patients before and after chemotherapy reveals chemoresistance-associated genes and pathways. Jaana Oikkonen, University of Helsinki, Helsinki, Finland.

A60 Phylogenetic analyses reveal variable patterns of tumor evolution in HGSOC. Jaana Oikkonen, University of Helsinki, Helsinki, Finland.
A61 FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy. Duygu Ozmadenci, University of California San Diego Moores Cancer Center, La Jolla, CA, USA.

A62, PR02 Proteogenomic approach to identify mechanisms of platinum refractoriness in high grade serous ovarian cancers. Amanda Paulovich, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

A63 Whole-genome CRISPR/CAS9 screen using patient samples reveals JunB as a unique genetic liability. David Pepin, Massachusetts General Hospital, Boston, MA, USA.

A64 Extracellular matrix proteins increase invasive growth and chemotherapy resistance of ovarian cancer cells. Elina Pietilä, University of Helsinki, Helsinki, Finland.

A65 Spatial characterization of drug resistance in ovarian cancer. Kathleen Pishas, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

A66 Repeatome profiling in high-grade serous ovarian cancer reveals abundant repeat non-coding RNA expression. Rebecca Porter, Massachusetts General Hospital Cancer Center, Boston, MA, USA.

A67 Understanding HIF1A-mediated therapy in clear-cell ovarian cancer. Colles Price, Dana Farber Cancer Institute, Broad Institute of MIT and Harvard, Boston, MA, USA.

A68 Increasing intracellular glucose levels decreased expression of Enolase-I promoting cisplatin resistance in ovarian cancer cells. Robert Rabelo-Fernandez, University of Puerto Rico at Rio Piedras, San Juan, PR, USA.

A69 Role of mitochondrial-STAT3 in promoting chemoresistance by modulating the energy metabolism in ovarian cancer. Ramandeep Rattan, Henry Ford Hospital, Detroit, MI, USA.

A70 Studying the signaling pathways of tumorigenic epithelial fallopian tube subpopulations during early tumorigenesis. Angela Russo, University of Illinois at Chicago, Chicago, IL, USA.

A71, PR13 Inhibition of RNA polymerase I transcription activates targeted DNA damage response and enhances the efficacy of PARP inhibitors in high-grade serous ovarian cancer. Elaine Sanij, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

A72 Combination ATR and PARP inhibitor (CAPRI) for recurrent, platinum-resistant ovarian cancer. Payal Shah, University of Pennsylvania, Philadelphia, PA, USA.
A73 BCL-XL dependency in a subset of ovarian clear-cell carcinoma cell lines. Elizabeth Stover, Dana-Farber Cancer Institute, Boston, MA, USA.

A74 The HIV protease inhibitor nelfinavir, alone or in combination with the proteasome inhibitor bortezomib, is cytotoxic to high-grade serous ovarian cancer cells regardless of platinum sensitivity. Carlos Telleria, McGill University, Montreal, QC, Canada.


A76 Role of frizzled-7 in platinum tolerance ovarian cancer. Yinu Wang, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

A77 Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high grade serous ovarian carcinoma. Zachary Watson, University of Colorado, Aurora, CO, USA.

A78 Preexisting, poly-resistant cancer stem cells in high-grade serous ovarian cancer. Wa Xian, University of Texas, Houston, TX, USA.

A79 A novel small molecule LLL12B inhibits STAT3 Phosphorylation and sensitizes ovarian cancer cell to cisplatin and paclitaxel treatment. Ruijie Zhang, University of Maryland School of Medicine, Baltimore, MD, USA.

A80 Targeting ovarian cancer stem cell by Dot1L inhibition. Yaqi Zhang, Northwestern University, Chicago, IL, USA.

A81 Targeting EZH2/DAB2IP/Wnt axis in ovarian cancer stem cells. Xingyue Zong, Indiana University School of Medicine, Bloomington, IN, USA.
B01 Optimizing chemotherapy for the integration of immune therapy in ovarian cancer: Enriching effector T-cells in the peritoneal tumor microenvironment using the route of cisplatin administration (IV vs. IP). Henning De May, University of New Mexico School of Medicine, Albuquerque, NM, USA.

B02 miR-181a initiates and perpetuates oncogenic transformation through the regulation of innate immune signaling. Analisa Difeo, University of Michigan, Ann Arbor, MI, USA.

B03 Immunotherapy of ovarian cancer with glycomimetic peptides. J. Kenneth Hoober, Susavion Biociences, Inc., Tempe, AZ, USA.

B04 Immune modeling analysis identifies ICOS and CTLA-4 as predictive biomarkers in serous epithelial ovarian cancer. Nicole James, Women and Infants Hospital, Providence, RI, USA.

B05 Induction of DNA damage in high-grade serous carcinoma induces type I interferon signaling. Karen McLean, University of Michigan, Ann Arbor, MI, USA.

B06, PR09 An unexpectedly effective immunotherapy strategy for ovarian cancer. Jogender Tushir-Singh, University of Virginia, Charlottesville, VA, USA.

B07 Ovarian cancer stem like cells and alternately activated macrophages reciprocally interact through the WNT pathway to promote pro-tumoral and malignant phenotypes in 3D engineered microenvironments. Geeta Mehta, University of Michigan, Ann Arbor, MI, USA.

B08, PR05 Patient-derived tumoroids for exploration of the ovarian cancer stem cell regulation, chemoresistance, and tumor heterogeneity. Geeta Mehta, University of Michigan, Ann Arbor, MI, USA.


B10, PR06 Dissecting mechanisms of replication fork stabilization in patient-derived high-grade serous organoid cultures and their impact on therapeutic sensitivity and the immune-tumor interaction. Sarah Hill, Dana-Farber Cancer Institute, Boston, MA, USA.

B11 Collective extrusion initiates dissemination in organotypic model of high-grade serous carcinoma. Marcin Iwanicki, Stevens Institute of Technology, Hoboken, NJ, USA.
B12 3D perfusion bioreactor system as a model for studying cell biology of Ovarian Cancer. Alba Martinez, University of Alabama at Birmingham, Birmingham, AL, USA.

B14 Atovaquone targets STAT3 in ovarian cancer spheroids. Kayli Neil, University of New Hampshire, Durham, NH, USA.

B15 BRCA haploinsufficiency promotes gluconeogenesis in fallopian tube epithelial cells. Iru Paudel, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA.

B16 STAT3 promotes ovarian cancer spheroid growth and metastasis. David Walker, University of New Hampshire, Durham, NH, USA.

B17 Modeling ovarian cancer in mice using in vivo electroporation and CRISPR-mediated genome editing. Yojiro Yamanaka, McGill University Goodman Cancer Research Centre, Montreal, QC, Canada.

B18 Transcriptional profiling of tumor stroma using ovarian cancer PDX models with induced platinum-resistance. Valentina Zanfagnin, Mayo Clinic, Rochester, MN, USA.

B19, PR12 Genetic aberrations dictate distinct tumor immune landscape and chemosensitivity in HGSOC. Shuang Zhang, Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA.


B21 Oncogenic BRAF and KRAS mutations in endosalpingiosis. M. Herman Chui, Johns Hopkins Medical Institutions, Baltimore, MD, USA.

B22 Development of the first ovarian carcinosarcoma patient derived xenograft and tissue organoid model to predict clinical response to chemotherapy. Justin Gorski, University of Kentucky, Lexington, KY, USA.
Poster Session B
Sunday, Sept. 15, 2019
12:30-3:30 p.m.

B23 CDK4/6 and MEK inhibitor combination in low-grade serous ovarian cancer cell lines. Joshua Hoenisch, University of British Columbia, Vancouver, BC, Canada.

B24, PR11 Dual blockade of BRD4 and the ATR/WEE1 pathway exploits ARID1A loss in clear cell ovarian cancers. Yasuto Kinose, Penn Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

B25 SMARCA4/BRG1 and AP-1 co-regulate an epithelial-like signature in small cell carcinoma of ovary, hypercalcemic type (SCCOHT). Krystal Orlando, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

B26 The natural history of ovarian high-grade serous carcinoma from time effects of ovulation inhibition and progesterone clearance of p53-defective lesions. Tang-Yuan Chu, Buddhist Tzu Chi General Hospital, Hualien, Taiwan, Republic of China.

B27 Cellular retinoic acid binding protein 2 (CRABP2) is a novel biomarker and potential therapeutic target for high-grade serous ovarian carcinomas. Daniele Chaves-Moreira, University of Pennsylvania, Philadelphia, PA, USA.

B28 Optimizing DNA processing and ovarian cancer methylation-specific PCR assays for the detection of early-stage ovarian cancer. Caroline Ford, UNSW Sydney, Sydney, NSW, Australia.

B29 Ovarian hormones regulate C/EBPD induced EMT/MET transition in the human fallopian tube epithelia. Sophia George, Miller School of Medicine, University of Miami Sylvester Comprehensive Cancer, Miami, FL, USA.


B31 Endocervical microRNA profiling for detection of ovarian cancer. Alexandra Harris, University of Virginia, Charlottesville, VA, USA.

B32 Are ovarian cancer risk factors different for women with endometriosis? Alice Lee, California State University, Fullerton, Fullerton, CA, USA.

B33 Reproductive factors and risk of ovarian cancer: The Singapore Chinese health study. Ming Lei, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Poster Session B
Sunday, Sept. 15, 2019
12:30-3:30 p.m.

B34 LINC00886, a risk locus-associated long non-coding RNA, promotes ovarian cancer progression. Koji Nakamura, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.

B35 Dietary flaxseed supplementation in ovarian cancer: Elucidating the molecular actions of its biologically derived active compounds. Purab Pal, Southern Illinois University School of Medicine, Carbondale, IL, USA.

B36 Anti-malarial agent, atovaquone, inhibits cancer cell proliferation by targeting oxidative phosphorylation and is a candidate for chemoprevention and chemotherapy of ovarian cancer. Manish Patankar, University of Wisconsin-Madison, Madison, WI, USA.

B37 Germline mutations in new susceptibility genes for non-high-grade serous ovarian cancer. Marina Pavanello, School of Women’s and Children’s Health, University of New South Wales, Sydney, NSW, Australia.

B38 Use of progestin-only injectable contraceptive is associated with reduced risk of ovarian cancer in the Ovarian Cancer Association Consortium. Minh Tung Phung, University of Michigan School of Public Health, Ann Arbor, MI, USA.

B39 Family history of ovarian cancer and healthcare-seeking behavior: Does having a family history prompt women to seek health care professional advice? Sun Hee Rim, National Center for Chronic Disease and Public Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA.

B40 Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian cancer. Rosa Ana Risques, University of Washington, Seattle, WA, USA.

B41 Racial/ethnic disparities in epithelial ovarian cancer and its risk factors: the Multiethnic Cohort Study. Danja Sarink, University of Hawaii Cancer Center, Honolulu, HI, USA.

B42 Intrauterine device use and ovarian cancer risk. Naoko Sasamoto, Brigham and Women's Hospital, Boston, MA, USA.

B43 A serum protein biomarker signature for the detection of early stages of ovarian cancer. Amy Skubitz, University of Minnesota, Minneapolis, MN, USA.

B44, PR04 Analyses of Pax2 and Pax8 in maintaining oviduct epithelial homeostasis and fertility. Abdulsalam Soofi, University of Michigan, Ann Arbor, Michigan, USA.
Poster Session B
Sunday, Sept. 15, 2019
12:30-3:30 p.m.

B45 Anti-inflammatory actions of DHA via inhibition of the NF-kB pathway. Kara Starkweather, Southern Illinois University School of Medicine, Carbondale, Illinois, USA.

B46 Trends in stage at diagnosis for ovarian, fallopian tube, and serous primary peritoneal cancers, 2004 – 2015. Julie Townsend, Centers for Disease Control and Prevention, Atlanta, GA, USA.

B47 Physical activity and survival following diagnosis with ovarian cancer. Tianyi Wang, Moffitt Cancer Center, Tampa, FL, USA.

B48 Ovarian cancer risk in laying hens is reduced by dietary polyunsaturated fatty acids: implications for soluble E-cadherin, de novo lipogenesis, and mitochondrial metabolism. Chris Weston, Southern Illinois University School of Medicine, Carbondale, IL, USA.

B49 Effects of exercise on ovarian cancer initiation and progression. Yang Yang-Hartwich, Yale School of Medicine, New Haven, CT, USA.

B50 Direct interrogation of the incessant ovulation hypothesis in a high-fidelity mouse model of high-grade serous cancer. Yali Zhai, University of Michigan, Ann Arbor, MI, USA.

B51 Distinct cancer-associated fibroblast states drive clinical outcomes in high-grade serous ovarian cancer and are regulated by TCF21. Laurie Ailles, Princess Margaret Cancer Centre, Toronto, ON, Canada.

B52 Inhibition of ovarian cancer spheroid adhesion using graphene oxide nanomaterials. Samira Azarin, University of Minnesota, Minneapolis, MN, USA.

B53, PR10 High-throughput functional and multi-omic single cell characterization to elucidate ovarian intratumor and microenvironmental heterogeneity. Kristin Beaumont, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

B54 Adipogenic chemokines, body mass index, and ovarian cancer survival. Alicia Beeghly-Fadiel, Vanderbilt University Medical Center, Nashville, TN, USA.

B55 Epigenetic reprogramming of mesenchymal stem cells by ovarian carcinoma to facilitate metastasis. Lan Coffman, University of Pittsburgh, Pittsburgh, PA, USA.
B56 Tissue transglutaminase/Frizzled receptor clusters regulate WNT transcriptional activity in ovarian cancer stem cells. Salvatore Condello, Indiana University School of Medicine, Indianapolis, IN, USA.

B57, PR08 High-grade serous ovarian tumor cells modulate natural killer cells to create an immune-tolerant microenvironment. Wendy Fantl, Stanford University, Stanford, CA, USA.


B59 Rac1 overexpression promotes epithelial to mesenchymal transition in ovarian cancer cells. Martha Grimes, University of New Mexico, Albuquerque, NM, USA.

B60 Pro-HGF and its activator confer a sustained transformation activity in ovulatory follicular fluid. Hsuan-Shun Huang, Buddhist Tzu Chi General Hospital, Hualien, Republic of China.

B61 The genotype of serous carcinomas shapes the tumor microenvironment and modulates responses to targeted and immune checkpoint therapies. Sonia Iyer, Whitehead Institute for Biomedical Research, Cambridge, MA, USA.

B62 Integrating highly multiplexed imaging with multi-omics data to uncover immunological vulnerabilities in high-grade serous ovarian cancer. Miikka Kilkkila, University of Helsinki, Helsinki, Finland.

B63 Lysophosphatidic acid as a mediator of ovarian cancer cell stemness. Yuliya Klymenko, Indiana University School of Medicine, Indianapolis, IN, USA.

B64 Targeting the pH regulators in the tumor microenvironment for ovarian cancer treatment. Arpita Kulshrestha, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA.

B65 Defining the tumor-immune landscape in a mouse model of high-grade serous carcinoma. Kevin McCool, University of Michigan, Ann Arbor, MI, USA.

B66 Paracrine interactions with microenvironmental fibroblasts promote ovarian cancer metastasis through downregulation of miR-4454. Anirban Mitra, Indiana University School of Medicine, Bloomington, IN, USA.
Poster Session B  
Sunday, Sept. 15, 2019  
12:30-3:30 p.m.

**B67 Analysis of function and inhibition of PGE2 pathway members MRP4 and EP4 in treatment of ovarian cancer.** Jocelyn Reader, University of Maryland School of Medicine, Baltimore, MD, USA.

**B68 Characterization of microtentacle phenotype and function in ovarian carcinomas.** Jocelyn Reader, University of Maryland, Baltimore, Baltimore, MD, USA.

**B69 Gut microbiome attenuates epithelial ovarian cancer growth and sensitivity to cisplatin: New opportunities for ovarian cancer treatments.** Ofer Reizes, Cleveland Clinic, Cleveland, OH, USA.

**B70 Rac1 as a therapeutic target in ovarian cancer.** Melanie Rivera, University of New Mexico, Albuquerque, NM, USA.

**B71 Investigating the role of PAX8 in modulating the tumor microenvironment of high-grade serous ovarian cancer.** Amrita Salvi, University of Illinois at Chicago, Chicago, IL, USA.

**B72 Single-cell analysis of chemotherapy resistance in ovarian cancer.** Timothy Starr, University of Minnesota, Minneapolis, MN, USA.

**B73 The search for EGFL6 receptor: Implications for tumor angiogenesis.** Mana Taki, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

**B74 Identifying conserved properties of the epithelial-mesenchymal transition in cancer using highly multiplexed single-cell RNA sequencing.** Barbara Vanderhyden, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, ON, Canada.

**B75, PR07 Reprogramming the tumor microenvironment with losartan to enhance immunotherapy of ovarian cancer.** Lei Xu, Massachusetts General Hospital, Boston, MA, USA.

**B76 Pyruvate dehydrogenase: A key to epigenetic regulation in CAFs.** Sara Zanivan, Cancer Research UK Beatson Institute, Glasgow, United Kingdom.

**B77 PORCN inhibition prolongs survival, decreases tumor burden, and alters the immune microenvironment in ovarian cancer.** Jaclyn Arquiette, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Poster Session B  
Sunday, Sept. 15, 2019  
12:30-3:30 p.m.

**B78 Improving chemotherapy response of immunologically cold high-grade serous ovarian cancer with loss of PTEN using STING agonist.** Noor Shakfa, Queen's University, Kingston, ON, Canada.

**B79 Effect of HIPEC on immune microenvironment in epithelial ovary cancer.** Arshi Rizwan, All India Institute of Medical Sciences, New-Delhi, India.

**B80 Predictive treatment response models for epithelial ovarian cancer: Comparison of 2D, 3D, and in vivo models.** Melica Nourmoussavi, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.